Mr. O’Dowd was appointed as a director of Puma Biotechnology on October 15, 2019. Since September 2016, he has served as President, Chief Executive Officer and a member of the Board of Directors of Neon Therapeutics, Inc. a publicly held clinical-stage immuno-oncology company developing neoantigen-based therapeutics.
Prior to that, Mr. O’Dowd spent more than 20 years in a variety of leadership roles at Novartis Pharmaceuticals Corporation. While at Novartis, he served as Country President and General Manager of the United Kingdom and Ireland from 2015 to 2016, he was Senior Vice President and Chief Commercial Officer of Novartis Oncology from 2011 to 2015, and he served as Vice President, Latin America Region Head for the Oncology business unit from 2009 to 2011. During his time as Chief Commercial Officer, Mr. O’Dowd was responsible for the global commercialization of Novartis’ oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence.
Mr. O’Dowd received an MBA from the Kellstadt Graduate School of Business at DePaul University in Chicago and a B.A. from Loyola University Chicago. He was selected as a director because of his significant experience and background in the life sciences industry and, in particular, commercialization of oncology drugs.
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024